Publications

Open-label, non-randomized, exploratory pre-operative window-of-opportunity trial to investigate the pharmacokinetics and pharmacodynamics of the smac mimetic Debio 1143 in patients…

Molecular screening of patients with FGFR alterations for a phase 1 (Ph1) study with the selective FGFR inhibitor (FGFRi) Debio…

Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123

DEBIO 1143, an IAP inhibitor, reverses ovarian cancer cells carboplatin resistance and triggers apoptotic or necroptotic cell death

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in…

SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer

Cellular pharmacokinetics (accumulation, subcellular distribution, efflux) of the FabI inhibitor Debio 1452 in J774 macrophages

Staphylococcal-selective antibiotic afabicin preserves the human gut microbiota

The inhibitor of apoptosis protein (IAP) antagonist Debio 1143 enhances the immune response to anti-PD1/L1 inhibitors in vitro and in…